Stoke Therapeutics, Inc. Preferred Stock, Shares Authorized
Stoke Therapeutics, Inc. (STOK) had Preferred Stock, Shares Authorized of 10.00 million shares as of 2019-12-31, per its 10-K filed 2020-03-23.
Discontinued › Balance Sheet › Preferred Stock, Number of Shares, Par Value and Other Disclosure
us-gaap:PreferredStockSharesAuthorized · last filed 2021-03-09
- 2019-12-31: Preferred Stock, Shares Authorized 10.00M shares.
- 2019-09-30: Preferred Stock, Shares Authorized 10.00M shares.
- 2019-06-30: Preferred Stock, Shares Authorized 10.00M shares.
- 2019-06-21: Preferred Stock, Shares Authorized 10.00M shares.
| Period end | Preferred Stock, Shares Authorized |
|---|---|
| 2019-12-31 | 10.00M shares 10-K · filed 2020-03-23 |
| 2019-09-30 | 10.00M shares 10-Q · filed 2019-11-12 |
| 2019-06-30 | 10.00M shares 10-Q · filed 2019-08-14 |
| 2019-06-21 | 10.00M shares 10-K · filed 2021-03-09 |
| 2019-06-06 | 10.00M shares 10-Q · filed 2020-11-12 |
| 2018-12-31 | 0.00 shares 10-K · filed 2020-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |